BioSyent (RX) News Today C$11.98 +0.23 (+1.96%) As of 07/4/2025 12:03 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesInsider TradesBuy This Stock RX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Biosyent Inc. Stock Price HistoryJune 19, 2025 | investing.comBloom Burton Forecasts BioSyent's FY2025 Earnings (CVE:RX)May 24, 2025 | marketbeat.comBloom Burton Forecasts BioSyent's FY2026 Earnings (CVE:RX)May 23, 2025 | marketbeat.comBioSyent (CVE:RX) Has Announced A Dividend Of CA$0.05May 19, 2025 | finance.yahoo.comBioSyent (CVE:RX) Share Price Crosses Above 50 Day Moving Average - Time to Sell?May 18, 2025 | marketbeat.comHere's Why We Think BioSyent (CVE:RX) Is Well Worth WatchingMay 15, 2025 | finance.yahoo.comBioSyent (CVE:RX) Shares Cross Below 50-Day Moving Average - Here's What HappenedApril 24, 2025 | marketbeat.comCould The Market Be Wrong About BioSyent Inc. (CVE:RX) Given Its Attractive Financial Prospects?April 18, 2025 | finance.yahoo.comBioSyent (CVE:RX) Shares Pass Above 50 Day Moving Average - Here's What HappenedApril 5, 2025 | marketbeat.comFeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive YearApril 1, 2025 | markets.businessinsider.comBioSyent (CVE:RX) Share Price Crosses Above Fifty Day Moving Average - Here's WhyMarch 28, 2025 | marketbeat.comFY2026 Earnings Forecast for BioSyent Issued By Bloom BurtonMarch 20, 2025 | marketbeat.comFY2025 EPS Estimates for BioSyent Increased by Bloom BurtonMarch 19, 2025 | marketbeat.comBioSyent (CVE:RX) Share Price Crosses Below Fifty Day Moving Average - What's Next?March 11, 2025 | marketbeat.comBioSyent (CVE:RX) Stock Passes Above Fifty Day Moving Average - Here's WhyMarch 2, 2025 | marketbeat.comBioSyent (CVE:RX) Stock Crosses Below 50 Day Moving Average - Time to Sell?February 22, 2025 | marketbeat.comBioSyent (CVE:RX) Share Price Passes Below Fifty Day Moving Average - Should You Sell?February 13, 2025 | marketbeat.comBioSyent (CVE:RX) Shares Pass Below 50 Day Moving Average - Time to Sell?February 5, 2025 | marketbeat.comBioSyent (CVE:RX) Stock Passes Above Two Hundred Day Moving Average - Should You Sell?January 28, 2025 | marketbeat.comBioSyent (CVE:RX) Stock Passes Above 50 Day Moving Average - Time to Sell?January 10, 2025 | marketbeat.comBioSyent (CVE:RX) Stock Price Passes Above Fifty Day Moving Average - What's Next?January 10, 2025 | marketbeat.comBioSyent (CVE:RX) Share Price Passes Above 50-Day Moving Average - What's Next?January 2, 2025 | marketbeat.comFAX Capital Corp. Sells 112,400 Shares of BioSyent Inc. (CVE:RX) StockDecember 24, 2024 | insidertrades.comBioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 112,400 SharesDecember 23, 2024 | marketbeat.comInvesting in BioSyent (CVE:RX) five years ago would have delivered you a 110% gainDecember 15, 2024 | uk.finance.yahoo.comBioSyent (CVE:RX) Sets New 52-Week High - Time to Buy?December 13, 2024 | marketbeat.comBioSyent Inc. (CVE:RX) Senior Officer Sells C$55,628.75 in StockDecember 13, 2024 | insidertrades.comInsider Selling: BioSyent Inc. (CVE:RX) Insider Sells 65,000 Shares of StockNovember 27, 2024 | insidertrades.comBioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 230,800 SharesNovember 26, 2024 | insidertrades.comFY2024 Earnings Estimate for BioSyent Issued By Bloom BurtonNovember 25, 2024 | marketbeat.comBioSyent Inc. (RX.V)November 24, 2024 | finance.yahoo.comBioSyent Inc. (CVE:RX) Will Pay A CA$0.045 Dividend In Four DaysNovember 24, 2024 | finance.yahoo.comCalculating The Fair Value Of BioSyent Inc. (CVE:RX)November 22, 2024 | finance.yahoo.comBioSyent Inc. (BIOYF)November 21, 2024 | finance.yahoo.comBioSyent (CVE:RX) Stock Crosses Below 50-Day Moving Average - Time to Sell?November 21, 2024 | marketbeat.comBioSyent Inc.November 13, 2024 | wsj.comBioSyent (CVE:RX) Stock Passes Below Fifty Day Moving Average - What's Next?November 13, 2024 | marketbeat.comBioSyent (CVE:RX) Sets New 1-Year High - Should You Buy?November 4, 2024 | marketbeat.comBioSyent Inc.'s (CVE:RX) Stock Is Going Strong: Is the Market Following Fundamentals?October 24, 2024 | finance.yahoo.comBioSyent (CVE:RX) Share Price Passes Above 50-Day Moving Average - Here's WhyOctober 12, 2024 | marketbeat.comBioSyent (CVE:RX) Hits New 52-Week High at $11.49October 3, 2024 | marketbeat.comSaatva Rx Mattress Review 2024: A Luxury Bed Designed for People With Chronic Health ConditionsOctober 1, 2024 | cnet.comShould You Be Adding BioSyent (CVE:RX) To Your Watchlist Today?September 26, 2024 | finance.yahoo.comBioSyent Inc. to Post FY2024 Earnings of $0.59 Per Share, Bloom Burton Forecasts (CVE:RX)September 25, 2024 | marketbeat.comInsider Selling: BioSyent Inc. (CVE:RX) Director Sells 2,320 Shares of StockSeptember 24, 2024 | insidertrades.comBioSyent Announces Agreement to Purchase Tibelia® (tibolone) AssetsSeptember 20, 2024 | finance.yahoo.comBioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 500,000 SharesSeptember 4, 2024 | insidertrades.comInsider Selling: BioSyent Inc. (CVE:RX) Insider Sells 500,000 Shares of StockSeptember 3, 2024 | marketbeat.comBioSyent (CVE:RX) Has Announced A Dividend Of CA$0.045August 30, 2024 | finance.yahoo.comBioSyent Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In LineAugust 28, 2024 | finance.yahoo.com Get BioSyent News Delivered to You Automatically Sign up to receive the latest news and ratings for RX and its competitors with MarketBeat's FREE daily newsletter. Email Address RX Media Mentions By Week RX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RX News Sentiment▼0.000.54▲Average Medical News Sentiment RX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RX Articles This Week▼01▲RX Articles Average Week Get BioSyent News Delivered to You Automatically Sign up to receive the latest news and ratings for RX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tilray Brands News Aurora Cannabis News Canopy Growth News Cipher Pharmaceuticals News Organigram News Cardiol Therapeutics News HLS Therapeutics News SugarBud Craft Growers News Medexus Pharmaceuticals News Willow Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CVE:RX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioSyent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
